Technology
Health
Pharmaceutical
Sage Therapeutics
$165.629876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$165.62
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$1.27 (0.77%) As of 2:13 PM EDT today
+$1.27 (0.77%) Today
Why Robinhood?
You can buy or sell SAGE and other stocks, options, ETFs, and crypto commission-free!
About SAGE
SAGE Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. Read More The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.
CEO
Employees
637
Headquarters
Cambridge, Massachusetts
Founded
2010
Market Cap
8.49B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
344.09K
High Today
$166.53
Low Today
$162.41
Open Price
$164.34
Volume
138.64K
52 Week High
$193.56
52 Week Low
$79.88
Collections
Technology
Health
Pharmaceutical
Therapy
Medical
Biopharmaceutical
2014 IPO
US
SAGE News
Price Paid on Robinhood
15% Higher
Right Now
52 Week Low
$79.88
Average Price Paid
$144.23
52 Week High
$177.14
Analyst Ratings
89%
of 19 ratings
Buy
89%
Hold
5%
Sell
5%
SAGE Earnings
-$3.38
-$2.37
-$1.37
-$0.36
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
-$3.33 per share
Actual
-$3.28 per share